Saquinavir

Saquinavir Struktur
127779-20-8
CAS-Nr.
127779-20-8
Englisch Name:
Saquinavir
Synonyma:
FLUNIXIN;FLUNIXINE;Sch 52852;SAQUINAVIR;SAGUINAVIR;Ro 31-8959/000;Saquinavir USP/EP/BP;SAQUINAVIR(RO 31-8959);Ro-31-8959/003:Invirase;Saquinavir Solution, 100ppm
CBNumber:
CB2161048
Summenformel:
C38H50N6O5
Molgewicht:
670.84
MOL-Datei:
127779-20-8.mol

Saquinavir Eigenschaften

alpha 
D20 -55.9° (c = 0.5 in methanol)
Siedepunkt:
1015.0±65.0 °C(Predicted)
Dichte
1.211±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
Löslichkeit
DMSO : 100 mg/mL (149.07 mM; Need ultrasonic)
Aggregatzustand
Powder
pka
11.05±0.46(Predicted)
Wasserlöslichkeit
35.8mg/L(25 ºC)
BCS Class
4
CAS Datenbank
127779-20-8(CAS DataBase Reference)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H314 Verursacht schwere Verätzungen der Haut und schwere Augenschäden. Ätzwirkung auf die Haut Kategorie 1B Achtung GHS hazard pictogramssrc="/GHS05.jpg" width="20" height="20" /> P260,P264, P280, P301+P330+ P331,P303+P361+P353, P363, P304+P340,P310, P321, P305+ P351+P338, P405,P501
Sicherheit
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P301+P330+P331 BEI VERSCHLUCKEN: Mund ausspülen. KEIN Erbrechen herbeiführen.
P303+P361+P353 BEI BERÜHRUNG MIT DER HAUT (oder dem Haar): Alle kontaminierten Kleidungsstücke sofort ausziehen. Haut mit Wasser abwaschen oder duschen.
P363 Kontaminierte Kleidung vor erneutem Tragen waschen.
P405 Unter Verschluss aufbewahren.
P501 Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Saquinavir Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Saquinavir mesylate, the first HIV protease inhibitor to reach the market, was launched in the U.S.A.. It is indicated for use in combination with approved nucleoside analogs for the treatment of advanced HIV infection. Saquinavir, a transition state analog of Phe-Pro, is a very potent and competitive inhibitor of HIV-1 and HIV-2 proteases with high specificity. Saquinavir inhibits the last stage in the replication process of HIV and prevents virion maturation in both acute and chronically infected cells. Combination of saquinavir with the nucleoside analogs such as zidovudine (AZT) or/and zalcitabine which inhibit the enzyme reverse transcriptase and target at an earlier stage in the HIV replication process, shows a greater than additive effect in increase in CD4 cell counts and reduction in viral load, with the combination delaying the onset of resistance to either drug alone. Saquinavir is well tolerated alone and in combination with A n .

Verwenden

Antiviral (HIV protease inhibitor).

Definition

ChEBI: An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin- (1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N2(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.

Indications

Saquinavir is a potent inhibitor of HIV-1 and HIV-2 protease. Fortovase, a soft gel preparation of saquinavir, has largely replaced saquinavir mesylate capsules (Invirase) because it has improved bioavailability. Saquinavir is usually well tolerated and most frequently produces mild gastrointestinal side effects.

Acquired resistance

Resistance is associated with an amino acid substitution at position 48 in the HIV protease (G48V). An L90M mutation also confers resistance, as it does for most protease inhibitors. Saquinavir-resistant isolates from patients on long-term therapy often show cross-resistance to other protease inhibitors.

Allgemeine Beschreibung

Saquinavir (Invirase) is well tolerated following oral administration.Absorption of saquinavir is poor but is increasedwith a fatty meal. The drug does not distribute intothe CSF, and it is approximately 98% bound to plasma proteins.Saquinavir is extensively metabolized by the firstpasseffect. Bioavailability is 4% from a hard capsule and12% to 15% from a soft capsule. Saquinavir lowers p24antigen levels in HIV-infected patients, elevates CD4+counts, and exerts a synergistic antiviral effect when combinedwith RT inhibitors such as AZT and ddC.Although HIV-1 resistance to saquinavir and other HIVPIs occurs in vivo, it is believed to be less stringent andless frequent than resistance to the RT inhibitors.Nevertheless,cross-resistance between different HIV PIsappears to be common and additive,suggesting thatusing combinations of inhibitors from this class would notconstitute rational prescribing. The drug should be used incombination with at least two other antiretroviral drugs tominimize resistance. Dosage forms are Invirase (hard capsule)and Fortovase (soft capsule).

Pharmazeutische Anwendungen

A peptidomimetic protease inhibitor formulated as the mesylate for oral use.

Pharmakokinetik

Oral absorption: c. 4%
Cmax 1200 mg thrice daily: c. 1–2.2 mg/L
Cmin 1200 mg thrice daily: c. 0.1–0.22 mg/L
Plasma half-life: c. 7–12 h
Volume of distribution: c. 700 L
Plasma protein binding: c. 98%
Absorption and distribution
It is poorly absorbed and penetrates poorly into the CNS. The semen:plasma ratio is 0.04. It is not known if it is distributed into human breast milk.
Metabolism and excretion
It is metabolized via CYP3A4, principally to mono- and dihydroxylated derivatives. Around 88% of the dose is excreted in feces and 1% in urine. Caution should be exercised in severe renal impairment and moderate hepatic impairment; use in decompensated hepatic impairment is contraindicated.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Nebenwirkungen

The most frequently reported adverse effects include abdominal discomfort, diarrhea and nausea. Ritonavir-boosted saquinavir is associated with a dyslipidemic profile characteristic of those treated with a boosted protease inhibitor requiring 200 mg of the ritonavir ‘booster’.

Saquinavir Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Saquinavir Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 158)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49390 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226
sales@hzclap.com CHINA 6313 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29016 58
AFINE CHEMICALS LIMITED
0571-85134551
info@afinechem.com CHINA 15377 58
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9338 58
XI'AN TIANGUANGYUAN BIOTECH CO., LTD.
+86-029-86333380 18829239519
sales06@tgybio.com China 959 58
Nextpeptide Inc
+86-0571-81612335 +8613336028439
sales@nextpeptide.com China 19915 58
InvivoChem
+1-708-310-1919 +1-13798911105
sales@invivochem.cn United States 6393 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418684 +8618949823763
sales@tnjchem.com China 25363 58

127779-20-8()Verwandte Suche:


  • (3S)-N-tert-Butyl-2-[(2R,3S)-3-[N-(2-quinolinylcarbonyl)-3-carbamoylalanylamino]-2-hydroxy-4-phenylbutyl]-1,2,3,4,4aβ,5,6,7,8,8aβ-decahydroisoquinoline-3α-carboxamide
  • (4aS,8aβ)-N-tert-Butyldecahydro-2-[(2R,3S)-2-hydroxy-4-phenyl-3-[[(2S)-3-carbamoyl-2-(2-quinolinylcarbonylamino)propanoyl]amino]butyl]isoquinoline-3α-carboxamide
  • Saquinavir & Saquinavir Mesylate
  • ButanediaMide,N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-diMethylethyl)aMino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylMethyl)propyl]-2-[(2-quinolinylcarbonyl)aMino]-,(2S)-
  • 2-[[2-METHYL-3-(TRIFLUOROMETHYL)PHENYL]AMINO]PYRIDINE-3-CARBOXYLIC ACID
  • (2S)-N-[(2S,3R)-4-[(3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)-3,4,4A,5,6,7,8,8A-OCTAHYDRO-1H-ISOQUINOLIN-2-YL]-3-HYDROXY-1-PHENYL-BUTAN-2-YL]-2-(QUINOLINE-2-CARBONYLAMINO)BUTANEDIAMIDE
  • FLUNIXINE
  • SAGUINAVIR
  • SAQUINAVIR
  • n1-[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide
  • SAQUINAVIRMESYLATE(SUBJECTTOPATENTFREE)
  • (S)-N-[(aS)-a-[(1R)-2-[(3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl]-1-hydroxyethyl]phenethyl]-2-quinaldamidosuccinamide
  • Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI)
  • Butanediamide, N1-[3-[3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[2[1R*(R*),2S*],3a,4ab,8ab]]-
  • Ro 31-8959/000
  • Sch 52852
  • Ro-31-8959/003:Invirase
  • Saquinavir Solution, 100ppm
  • N-[4-[3-[(tert-butylamino)-oxomethyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[[oxo(2-quinolinyl)methyl]amino]butanediamide
  • SAQUINAVIR(RO 31-8959)
  • Saquinavir USP/EP/BP
  • Saquinavir D6Q: What is Saquinavir D6 Q: What is the CAS Number of Saquinavir D6 Q: What is the storage condition of Saquinavir D6 Q: What are the applications of Saquinavir D6
  • FLUNIXIN
  • (S)-N1-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide
  • 127779-20-8
  • 12779-20-8
  • C38H50N6O5
  • Saquinavir
  • API
  • Active Pharmaceutical Ingredients
  • peptides
  • Pharmaceutical
Copyright 2019 © ChemicalBook. All rights reserved